{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:28:32Z","timestamp":1772699312675,"version":"3.50.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"To investigate trends in prevalence of various human papillomavirus types in order to assess the unmet clinical needs for women affected by human papillomavirus-related disease. Data of consecutive 15 138 patients undergoing human papillomavirus DNA testing from 1998 to 2018 were retrospectively identified. Human papillomavirus types were classified at high-risk according to the classification of the International Agency for Research on Cancer. The International Agency for Research on Cancer included seven human papillomavirus types covered by nine-valent vaccine and five not yet covered by any available vaccines. Overall, 4159 (65.3%), 1500 (23.5%) and 714 (11.2%) women had human papillomavirus types covered by nine-valent vaccination, not covered by nine-valent vaccination and co-infections of human papillomavirus types of both groups. At least one high-risk human papillomavirus type(s) was detected in 1241 patients with genital dysplasia: 832 (67.1%), 291 (23.4%) and 118 (9.5%) women had human papillomavirus types covered by nine-valent vaccination, not covered by nine-valent vaccination and co-infections of human papillomavirus types of both groups. Over the twenty-year study period, the number of human papillomavirus types not covered by nine-valent vaccine increased dramatically (from 4 to 16%; P<\/jats:italic> < 0.001, P<\/jats:italic> for trend). Similarly, looking at patients with genital dysplasia, high-risk human papillomavirus types not covered by nine-valent vaccine increased from 3 to 13% (P<\/jats:italic> < 0.001, P<\/jats:italic> for trend). Our data highlight that human papillomavirus types covered by nine-valent vaccine represent are the main types associated with genital dysplasia. However, over the study period, we observed an increasing prevalence of confections and high-risk human papillomavirus types not covered by the nine-valent vaccine, thus suggesting the need of developing more complete vaccines against human papillomavirus.<\/jats:p>","DOI":"10.1097\/cej.0000000000000565","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T16:28:10Z","timestamp":1579192090000},"page":"452-457","source":"Crossref","is-referenced-by-count":2,"title":["Trends in prevalence in human papillomavirus types and their association with cervical dysplasia: an analysis on 15 138 women over 20 years"],"prefix":"10.1097","volume":"29","author":[{"given":"Giorgio","family":"Bogani","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Chiappa","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Pinelli","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Signorelli","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Taverna","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Ditto","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2019.05.024","article-title":"Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.","volume":"154","author":"Aro","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/CEJ.0000000000000475","article-title":"Nomogram-based prediction of cervical dysplasia persistence\/recurrence.","volume":"28","author":"Bogani","year":"2019","journal-title":"Eur J Cancer Prev"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ijgo.12170","article-title":"Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology.","volume":"138","author":"Bogani","year":"2017","journal-title":"Int J Gynaecol Obstet"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ijgo.12546","article-title":"Potential impact of introducing a nonavalent HPV vaccination.","volume":"142","author":"Bogani","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2018.05.019","article-title":"Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.","volume":"36","author":"Dillner","year":"2018","journal-title":"Vaccine"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2.","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pvr.2018.10.010","article-title":"Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016).","volume":"6","author":"Innes","year":"2018","journal-title":"Papillomavirus Res"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2019.04.032","article-title":"Human papillomavirus vaccination: the ESGO-EFC position paper of the european society of gynaecologic oncology and the european federation for colposcopy.","volume":"116","author":"Joura","year":"2019","journal-title":"Eur J Cancer"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.vaccine.2019.04.099","article-title":"Declines in HPV vaccine type prevalence in women screened for cervical cancer in the united states: evidence of direct and herd effects of vaccination.","volume":"37","author":"Markowitz","year":"2019","journal-title":"Vaccine"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in england using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016.","volume":"218","author":"Mesher","year":"2018","journal-title":"J Infect Dis"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:08:51Z","timestamp":1693616931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000565","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,15]]}}}